Preview

Российский журнал гериатрической медицины

Расширенный поиск

Особенности лечения воспалительных ревматических заболеваний у пожилых

https://doi.org/10.37586/2686-8636-3-2021-319-331

Полный текст:

Аннотация

В настоящее время увеличивается число пожилых людей с хроническими ревматическими заболеваниями. Отличительными особенностями данной популяции являются повышенный риск сердечно-сосудистых, опухолевых, инфекционных заболеваний, а также ятрогенных осложнений, при этом данная группа пациентов достаточно гетерогенна. Современные биологические и таргетные синтетические препараты, с одной стороны, дают новые, ранее недоступные, возможности лечения, с другой стороны, их использование сопряжено с риском побочных эффектов. В данном обзоре рассматриваются особенности назначения иммуносупрессивных препаратов у пожилых пациентов с ревматоидным артритом и спондилоартритами. Основой эффективного и безопасного подхода к использованию данных препаратов у пожилых может быть комплексный междисциплинарный подход с учетом гериатрических особенностей пациентов.

Об авторах

А. Д. Мешков
ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России, Российский геронтологический научно-клинический центр
Россия

Москва



В. С. Остапенко
ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России, Российский геронтологический научно-клинический центр
Россия

Остапенко Валентина Сергеевна, к.м.н., доцент кафедры болезней старения, научный сотрудник лаборатории общей гериатрии ОСП

Москва



Список литературы

1. Forouzanfar M.H. et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990– 2015: a systematic analysis for the Global Burden of Disease Study 2015 // Lancet. Lancet Publishing Group, 2016. Vol. 388, № 10053. P. 1659–1724.

2. Franceschi C. et al. Inflamm-aging. An evolutionary perspective on immunosenescence // Annals of the New York Academy of Sciences. New York Academy of Sciences, 2000. Vol. 908. P. 244–254.

3. McElhaney J.E., Effros R.B. Immunosenescence: what does it mean to health outcomes in older adults? // Current Opinion in Immunology. 2009. Vol. 21, № 4. P. 418–424.

4. Bressler R., Bahl J.J. Principles of Drug Therapy for the Elderly Patient // Mayo Clinic Proceedings. Elsevier Ltd, 2003. Vol. 78, № 12. P. 1564–1577.

5. Grimes D.A., Schulz K.F. Bias and causal associations in observational research // Lancet. Elsevier Limited, 2002. Vol. 359, № 9302. P. 248–252.

6. Soubrier M. et al. Elderly-onset rheumatoid arthritis // Joint Bone Spine. 2010. Vol. 77, № 4. P. 290–296.

7. El-Labban A.S. et al. Pattern of young and old onset rheumatoid arthritis (YORA and EORA) among a group of Egyptian patients with rheumatoid arthritis // Clin. Med. Insights Arthritis Musculoskelet. Disord. Libertas Academica Ltd., 2010. Vol. 3. P. 25–31.

8. Nieuwenhuis W.P. et al. Older age is associated with more MRI-detected inflammation in hand and foot joints // Rheumatol. (United Kingdom). Oxford University Press, 2016. Vol. 55, № 12. P. 2212–2219.

9. Chen D.Y. et al. Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: A comparison with youngeronset disease // Gerontology. 2009. Vol. 55, № 3. P. 250–258.

10. de Gonzalo-Calvo D. et al. Chronic inflammation as predictor of 1-year hospitalization and mortality in elderly population // Eur. J. Clin. Invest. Eur J Clin Invest, 2012. Vol. 42, № 10. P. 1037–1046.

11. Mueller R.B. et al. Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort // Rheumatology. 2014. Vol. 53, № 4. P. 671–677.

12. Innala L. et al. Age at onset determines severity and choice of treatment in early rheumatoid arthritis: A prospective study // Arthritis Res. Ther. BioMed Central Ltd., 2014. Vol. 16, № 2.

13. Huscher D. et al. Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: A matched-pairs analysis taking age and disease duration into account // Clin. Exp. Rheumatol. 2013. Vol. 31, № 2. P. 0251–0262.

14. Sekiguchi M. et al. Differences in predictive factors for sustained clinical remission with abatacept between younger and elderly patients with biologic-naive rheumatoid arthritis: Results from the abroad study // J. Rheumatol. Journal of Rheumatology, 2016. Vol. 43, № 11. P. 1974–1983.

15. Krams T. et al. Effect of age at rheumatoid arthritis onset on clinical, radiographic, and functional outcomes: The ESPOIR cohort // Jt. Bone Spine. Elsevier Masson SAS, 2016. Vol. 83, № 5. P. 511–515.

16. Smolen J.S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update // Ann. Rheum. Dis. 2017.

17. Strehl C. et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: Viewpoints from an EULAR task force // Annals of the Rheumatic Diseases. BMJ Publishing Group, 2016. Vol. 75, № 6. P. 952–957.

18. Ассоциация ревматологов России. Клинические рекомендации «Ревматоидный артрит». 2018.

19. Felson D.T. et al. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis // J. Rheumatol. J Rheumatol, 1995. Vol. 22, № 2. P. 218–223.

20. Saevarsdottir S. et al. Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: Results from the initial open-label phase of the SWEFOT trial // Ann. Rheum. Dis. 2011. Vol. 70, № 3. P. 469–475.

21. Alivernini S. et al. Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: Retrospective analysis of safety and adherence to treatment // Drugs and Aging. 2009. Vol. 26, № 5. P. 395–402.

22. Black R.J. et al. Half of UK patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: A retrospective drug utilisation study // Arthritis Res. Ther. BioMed Central Ltd., 2015. Vol. 17, № 1.

23. Palmowski Y. et al. «Official View» on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements // Arthritis Care Res. John Wiley and Sons Inc., 2017. Vol. 69, № 8. P. 1134–1141.

24. Fraenkel L. et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis // Arthritis Rheumatol. Arthritis Rheumatol, 2021. P. art.41752.

25. Genevay S. et al. Tolerance and effectiveness of anti-tumor necrosis factor α therapies in elderly patients with rheumatoid arthritis: A population-based cohort study // Arthritis Care Res. Arthritis Rheum, 2007. Vol. 57, № 4. P. 679–685.

26. Radovits B.J. et al. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis // Rheumatology. Oxford Academic, 2009. Vol. 48, № 8. P. 906–910.

27. Hetland M.L. et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry // Arthritis Rheum. Arthritis Rheum, 2010. Vol. 62, № 1. P. 22–32.

28. Filippini M. et al. Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: Long-term real-life data from the Lorhen registry // Biomed Res. Int. Hindawi Publishing Corporation, 2014. Vol. 2014.

29. Filippini M. et al. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: An observational study // Clin. Rev. Allergy Immunol. 2010. Vol. 38, № 2–3. P. 90–96.

30. Hyrich K.L. et al. Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register // Rheumatology. Rheumatology (Oxford), 2006. Vol. 45, № 12. P. 1558–1565.

31. Bathon J.M. et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis // J. Rheumatol. J Rheumatol, 2006. Vol. 33, № 2. P. 234–243.

32. Fleischmann R., Iqbal I. Risk: Benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis // Drugs and Aging. 2007. Vol. 24, № 3. P. 239–254.

33. Köller M.D. et al. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients // Rheumatology. Rheumatology (Oxford), 2009. Vol. 48, № 12. P. 1575–1580.

34. Edwards C.J. et al. Efficacy and Safety of Etanercept in Elderly Patients with Rheumatoid Arthritis: A Post-Hoc Analysis of Randomized Controlled Trials // Drugs and Aging. Springer International Publishing, 2019. Vol. 36, № 9. P. 853–862.

35. Wendler J. et al. Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): Six-year results from a prospective, multicentre, non-interventional study in 2,484 patients // Arthritis Res. Ther. BioMed Central Ltd., 2014. Vol. 16, № 2.

36. Payet S. et al. Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French society of rheumatology registry // Arthritis Care Res. John Wiley and Sons Inc, 2014. Vol. 66, № 9. P. 1289–1295.

37. Lahaye C. et al. Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French society of rheumatology’s ORA registry // Rheumatol. (United Kingdom). Oxford University Press, 2016. Vol. 55, № 5. P. 874–882.

38. Being Elderly Is Not a Predictive Factor of Discontinuation of Abatacept Due to Adverse Events in Rheumatoid Arthritis Patients with Concomitant Methotrexate: A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study — ACR Meeting Abstracts [Electronic resource]. URL: https://acrabstracts.org/abstract/being-elderly-is-not-a-predictivefactor-of-discontinuation-of-abatacept-due-to-adverse-events-inrheumatoid-arthritis-patients-with-concomitant-methotrexate-aretrospective-observational-study-based/ (accessed: 24.06.2021).

39. Analysis of the Efficacy, Safety and Continuation Rate of Abatacept in Elderly Patients with Rheumatoid Arthritis — ACR Meeting Abstracts [Electronic resource]. URL: https://acrabstracts.org/abstract/analysis-of-the-efficacy-safety-and-continuationrate-of-abatacept-in-elderly-patients-with-rheumatoid-arthritis/(accessed: 24.06.2021).

40. Pers Y.M. et al. Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis // Jt. Bone Spine. Elsevier Masson SAS, 2015. Vol. 82, № 1. P. 25–30.

41. Curtis J.R. et al. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis // Clin. Exp. Rheumatol. Clinical and Experimental Rheumatology S.A.S., 2017. Vol. 35, № 3. P. 0390–0400.

42. Fleischmann R. et al. Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis // RMD Open. BMJ, 2017. Vol. 3, № 2. P. e000546.

43. Van Onna M., Boonen A. The challenging interplay between rheumatoid arthritis, ageing and comorbidities // BMC Musculoskelet. Disord. BioMed Central Ltd., 2016. Vol. 17, № 1.

44. Widdifield J. et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. // Arthritis Care Res. (Hoboken). 2013. Vol. 65, № 3. P. 353–361.

45. Bernatsky S., Ehrmann Feldman D. Discontinuation of methotrexate therapy in older patients with newly diagnosed rheumatoid arthritis: Analysis of administrative health databases in Québec, Canada // Drugs and Aging. 2008. Vol. 25, № 10. P. 879–884.

46. Alarcón G.S. et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: A multicenter, casecontrol study // Ann. Intern. Med. American College of Physicians, 1997. Vol. 127, № 5. P. 356–364. 47. Kent P.D., Luthra H.S., Michet C.J. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis // J. Rheumatol. J Rheumatol, 2004. Vol. 31, № 9. P. 1727–1731.

47. Baker J.F. et al. Changes in Body Mass Related to the Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis // Arthritis Rheumatol. John Wiley and Sons Inc., 2016. Vol. 68, № 8. P. 1818–1827.

48. Cho S.K. et al. Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis // BMC Musculoskelet. Disord. BioMed Central, 2016. Vol. 17, № 1. P. 1–8.

49. Murota A. et al. Safety of biologic agents in elderly patients with rheumatoid arthritis // J. Rheumatol. Journal of Rheumatology, 2016. Vol. 43, № 11. P. 1984–1988.

50. Kawai V.K. et al. Changes in cotherapies after initiation of disease — Modifying antirheumatic drug therapy in patients with rheumatoid arthritis // Arthritis Care Res. 2011. Vol. 63, № 10. P. 1415–1424.

51. Busquets N. et al. Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. // Rheumatology (Oxford). Rheumatology (Oxford), 2011. Vol. 50, № 11. P. 1999–2004.

52. Komano Y. et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: A report from the registry of Japanese rheumatoid arthritis patients for longterm safety // J. Rheumatol. 2011. Vol. 38, № 7. P. 1258–1264.

53. Galloway J.B. et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: Updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly // Rheumatology. Rheumatology (Oxford), 2011. Vol. 50, № 1. P. 124–131.

54. Lane M.A. et al. TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis // Medicine (Baltimore). 2011. Vol. 90, № 2. P. 139–145.

55. Curtis J.R. et al. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high-versus lower-risk rheumatoid arthritis patients // Arthritis Care Res. 2012. Vol. 64, № 10. P. 1480–1489.

56. Schneeweiss S. et al. Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis // Arthritis Rheum. Arthritis Rheum, 2007. Vol. 56, № 6. P. 1754–1764.

57. Kawashima H. et al. Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis // Rheumatol. Int. Springer Verlag, 2017. Vol. 37, № 3. P. 369–376.

58. Toh S. et al. Comparative safety of infliximab and etanercept on the risk of serious infections: Does the association vary by patient characteristics? // Pharmacoepidemiol. Drug Saf. Pharmacoepidemiol Drug Saf, 2012. Vol. 21, № 5. P. 524–534.

59. Dixon W.G. et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR) // Ann. Rheum. Dis. 2010. Vol. 69, № 3. P. 522–528.

60. Kim H.W. et al. Comparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area // Clin. Rheumatol. Springer-Verlag London Ltd, 2014. Vol. 33, № 9. P. 1307–1312.

61. Lim C.H. et al. The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: A 15-year real world experience in Taiwan // PLoS One. Public Library of Science, 2017. Vol. 12, № 6.

62. Winthrop K.L. et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster // JAMA — J. Am. Med. Assoc. 2013. Vol. 309, № 9. P. 887–895.

63. Winthrop K.L. The emerging safety profile of JAK inhibitors in rheumatic disease // Nature Reviews Rheumatology. Nature Publishing Group, 2017. Vol. 13, № 4. P. 234–243.

64. Singh J.A. et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis // Arthritis Care Res. (Hoboken). 2016.

65. Vassilopoulos D. et al. Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: A long-term, prospective real-life study // Clin. Exp. Rheumatol. Clinical and Experimental Rheumatology S.A.S., 2016. Vol. 34, № 5. P. 893–900.

66. Национальный календарь профилактических прививок [Electronic resource]. URL: https://minzdrav.gov.ru/opendata/7707778246-natskalendarprofilakprivivok2015/visual (accessed: 25.06.2021).

67. Wolfe F., Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study // Arthritis Rheum. Arthritis Rheum, 2007. Vol. 56, № 9. P. 2886–2895.

68. Raaschou P. et al. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: Cohort study based on nationwide prospectively recorded data from Sweden // BMJ. BMJ Publishing Group, 2016. Vol. 352.

69. Nayak P. et al. Impact of Rheumatoid Arthritis on the Mortality of Elderly Patients Who Develop Cancer: A Population-Based Study // Arthritis Care Res. John Wiley and Sons Inc., 2017. Vol. 69, № 1. P. 75–83.

70. Solomon D.H., Mercer E., Kavanaugh A. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: A review of their methodologies and results // Arthritis and Rheumatism. 2012. Vol. 64, № 1. P. 21–32.

71. Haynes K. et al. Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases // Arthritis Rheum. 2013. Vol. 65, № 1. P. 48–58.

72. Askling J. et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor α therapies: Does the risk change with the time since start of treatment? // Arthritis Rheum. 2009. Vol. 60, № 11. P. 3180–3189.

73. Dreyer L. et al. Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides — A follow-up study from the DANBIO Registry // Ann. Rheum. Dis. 2013. Vol. 72, № 1. P. 79–82.

74. Askling J. et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: Meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data // Pharmacoepidemiol. Drug Saf. Pharmacoepidemiol Drug Saf, 2011. Vol. 20, № 2. P. 119–130.

75. Setoguchi S. et al. Tumor necrosis factor-α antagonist use and heart failure in elderly patients with rheumatoid arthritis // Am. Heart J. 2008. Vol. 156, № 2. P. 336–341.

76. Wu C.Y. et al. The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: A nationwide cohort study // Arthritis Res. Ther. BioMed Central Ltd., 2014. Vol. 16, № 5.

77. Amari W. et al. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. // Rheumatology (Oxford). Rheumatology (Oxford), 2011. Vol. 50, № 8. P. 1431–1439.

78. Crowson C.S. et al. Rheumatoid arthritis and cardiovascular disease // American Heart Journal. Mosby Inc., 2013. Vol. 166, № 4.

79. Lindhardsen J. et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: A Danish nationwide cohort study // Ann. Rheum. Dis. 2011. Vol. 70, № 6. P. 929–934.

80. Barnabe C., Martin B.J., Ghali W.A. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. // Arthritis care & research. 2011. Vol. 63, № 4. P. 522–529.

81. Herrinton L.J. et al. Association between anti-TNF-α therapy and all-cause mortality // Pharmacoepidemiol. Drug Saf. Pharmacoepidemiol Drug Saf, 2012. Vol. 21, № 12. P. 1311–1320.

82. Zhang J. et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis // Ann. Rheum. Dis. BMJ Publishing Group, 2016. Vol. 75, № 10. P. 1813–1818.

83. Van Staa T.P. et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis // Arthritis Rheum. Arthritis Rheum, 2006. Vol. 54, № 10. P. 3104–3112.

84. Bijlsma J.W.J., Buttgereit F. Adverse events of glucocorticoids during treatment of rheumatoid arthritis: Lessons from cohort and registry studies // Rheumatol. (United Kingdom). Oxford University Press, 2016. Vol. 55, № suppl 2. P. ii3–ii5.

85. Buckley L. et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid- Induced Osteoporosis // Arthritis Care Res. John Wiley and Sons Inc., 2017. Vol. 69, № 8. P. 1095–1110.

86. Баранова И.А., Торопцова Н.В., Лесняк O.M. Основные положения клинических рекомендаций «диагностика, профилактика и лечение глюкокортикоидного остеопороза у мужчин и женщин 18 лет и старше» // Остеопороз и остеопатии. Endocrinology Research Centre, 2014. Vol. 17, № 3. P. 34–37.

87. Smolen J.S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update // Ann. Rheum. Dis. BMJ Publishing Group, 2017. Vol. 76, № 6. P. 960–977.

88. Agca R. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update // Ann. Rheum. Dis. BMJ Publishing Group, 2016. Vol. 76, № 1. P. 17–28.

89. Dubost J.J., Sauvezie B. Late onset peripheral spondyloarthropathy // J. Rheumatol. J Rheumatol, 1989. Vol. 16, № 9. P. 1214–1217.

90. Toussirot É. Late-onset ankylosing spondylitis and spondylarthritis: An update on clinical manifestations, differential diagnosis and pharmacological therapies // Drugs and Aging. 2010. Vol. 27, № 7. P. 523–531.

91. Montilla C. et al. Clinical features of late-onset ankylosing spondylitis: Comparison with early-onset disease // J. Rheumatol. 2012. Vol. 39, № 5. P. 1008–1012.

92. Gladman D.D. et al. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome // Annals of the Rheumatic Diseases. BMJ Publishing Group, 2005. Vol. 64, № SUPPL. 2. P. 14–17.

93. Punzi L. et al. Clinical and laboratory manifestations of elderly onset psoriatic arthritis: A comparison with younger onset disease // Ann. Rheum. Dis. BMJ Publishing Group, 1999. Vol. 58, № 4. P. 226–229.

94. Kobak S. et al. Characteristics of Turkish patients with elderly onset psoriatic arthritis: A retrospective cohort study // Med. (United States). Lippincott Williams and Wilkins, 2017. Vol. 96, № 33.

95. Arumugam R., McHugh N.J. Mortality and causes of death in psoriatic arthritis // Journal of Rheumatology. 2012. Vol. 39, № SUPPL. 89. P. 32–35.

96. Ibáñez-Bosch R. et al. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients: a study based on carotid ultrasound // Rheumatol. Int. Springer Verlag, 2017. Vol. 37, № 1. P. 107–112.

97. Mathieu S., Pereira B., Soubrier M. Cardiovascular events in ankylosing spondylitis: An updated meta-analysis // Semin. Arthritis Rheum. W.B. Saunders, 2015. Vol. 44, № 5. P. 551–555. 99. Parsi K.K. et al. Are patients with psoriasis being screened for cardiovascular risk factors? A study of screening practices and awareness among primary care physicians and cardiologists // J. Am. Acad. Dermatol. 2012. Vol. 67, № 3. P. 357–362.

98. Kimball A.B. et al. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis // J. Am. Acad. Dermatol. 2012. Vol. 67, № 1. P. 76–85.

99. Hagberg K.W. et al. Rates of Cancers and Opportunistic Infections in Patients with Psoriatic Arthritis Compared with Patients Without Psoriatic Arthritis // J. Clin. Rheumatol. Lippincott Williams and Wilkins, 2016. Vol. 22, № 5. P. 241–247.

100. Balato N. et al. Managing moderate-to-severe psoriasis in the elderly // Drugs and Aging. Adis International Ltd, 2014. Vol. 31, № 4. P. 233–238.

101. Gross R.L. et al. A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large us cohort // Arthritis Rheumatol. John Wiley and Sons Inc., 2014. Vol. 66, № 6. P. 1472–1481.

102. Kathuria P., Gordon K.B., Silverberg J.I. Association of psoriasis and psoriatic arthritis with osteoporosis and pathological fractures // J. Am. Acad. Dermatol. Mosby Inc., 2017. Vol. 76, № 6. P. 1045-1053.e3.

103. Grozdev I.S. et al. Psoriasis in the elderly: From the Medical Board of the National Psoriasis Foundation // J. Am. Acad. Dermatol. 2011. Vol. 65, № 3. P. 537–545.

104. Wong J.W., Koo J.Y.M. The safety of systemic treatments that can be used for geriatric psoriasis patients: A review // Dermatology Research and Practice. 2012. Vol. 2012.

105. Piaserico S. et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients // Acta Derm. Venereol. Medical Journals/Acta D-V, 2014. Vol. 94, № 3. P. 293–297.

106. Garber C. et al. Biologic and conventional systemic therapies show similar safety and efficacy in elderly and adult patients with moderate to severe psoriasis // J. Drugs Dermatology. Journal of Drugs in Dermatology, 2015. Vol. 14, № 8. P. 846–852.

107. Menter A. et al. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis // J. Am. Acad. Dermatol. 2010. Vol. 63, № 3. P. 448–456.

108. Militello G. et al. Etanercept for the treatment of psoriasis in the elderly // J. Am. Acad. Dermatol. 2006. Vol. 55, № 3. P. 517–519.

109. Iervolino S. et al. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers // J. Rheumatol. 2012. Vol. 39, № 3. P. 568–573.

110. Chiricozzi A. et al. Efficacy and safety of infliximab in psoriatic patients over the age of 65 // Expert Opin. Drug Saf. Taylor and Francis Ltd, 2016. Vol. 15, № 11. P. 1459–1462.

111. Esposito M. et al. Efficacy and safety of subcutaneous antitumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: An observational long-term study // Dermatology. 2013. Vol. 225, № 4. P. 312–319.

112. Medina C. et al. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: An observational study from national BIOBADADERM registry // J. Eur. Acad. Dermatology Venereol. Blackwell Publishing Ltd, 2015. Vol. 29, № 5. P. 858–864.

113. Perlmutter A., Mittal A., Menter A. Tuberculosis and tumour necrosis factor-α inhibitor therapy: A report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians // British Journal of Dermatology. Br J Dermatol, 2009. Vol. 160, № 1. P. 8–15.

114. Hayashi M. et al. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis // J. Dermatol. Blackwell Publishing Ltd, 2014. Vol. 41, № 11. P. 974–980.

115. Megna M. et al. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period // Clinical and Experimental Dermatology. Blackwell Publishing Ltd, 2016. Vol. 41, № 5. P. 564–566.

116. Fiorentino D. et al. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry // J. Am. Acad. Dermatol. Mosby Inc., 2017. Vol. 77, № 5. P. 845–854.e5.

117. Gossec L. et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update // Ann. Rheum. Dis. BMJ Publishing Group, 2016. Vol. 75, № 3. P. 499–510.

118. Coates L.C. et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis // Arthritis Rheumatol. John Wiley and Sons Inc., 2016. Vol. 68, № 5. P. 1060–1071.

119. Smolen J.S. et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force // Ann. Rheum. Dis. BMJ Publishing Group, 2018. Vol. 77, № 1. P. 3–17.

120. Коротаева Т.В. et al. Псориатический артрит. Клинические рекомендации по диагностике и лечению // Современная ревматолога. IMA Press, LLC, 2018. Vol. 12, № 2. P. 22–35.

121. Smith C.H. et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 // Br. J. Dermatol. Blackwell Publishing Ltd, 2017. Vol. 177, № 3. P. 628–636.

122. Tutuncu Z. et al. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? // Ann. Rheum. Dis. 2006. Vol. 65, № 9. P. 1226–1229.

123. Ranganath V.K. et al. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis // Rheumatol. (United Kingdom). Oxford University Press, 2013. Vol. 52, № 10. P. 1809–1817.

124. Morsley K., Kilner T., Steuer A. Biologics Prescribing for Rheumatoid Arthritis in Older Patients: A Single-Center Retrospective Cross-Sectional Study // Rheumatol. Ther. Springer Nature, 2015. Vol. 2, № 2. P. 165–172.

125. Soubrier M. et al. Vascular effects of nonsteroidal antiinflammatory drugs // Joint Bone Spine. 2013. Vol. 80, № 4. P. 358–362.

126. Ткачева О.Н. et al. Клинические рекомендации “Хроническая боль у пациентов пожилого и старческого возраста”.

127. The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study — Full Text View — ClinicalTrials.gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/NCT02585258 (accessed: 24.06.2021).

128. Harrold L.R. et al. Time trends in medication use and expenditures in older patients with rheumatoid arthritis // Am. J. Med. 2012. Vol. 125, № 9.

129. Predictors of Earlier Biologic Initiation Among Patients with Rheumatoid Arthritis Starting Methotrexate — ACR Meeting Abstracts [Electronic resource]. URL: https://acrabstracts.org/abstract/predictors-of-earlier-biologic-initiation-among-patientswith-rheumatoid-arthritis-starting-methotrexate/ (accessed: 24.06.2021).

130. Putrik P. et al. Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (norway): Results from norwegian cohort study NOR-DMARD // Rheumatol. (United Kingdom). Oxford University Press, 2016. Vol. 55, № 7. P. 1217–1224.

131. Yelin E. et al. Sociodemographic, disease, health system, and contextual factors affecting the initiation of biologic agents in rheumatoid arthritis: A longitudinal study // Arthritis Care Res. John Wiley and Sons Inc., 2014. Vol. 66, № 7. P. 980–989.

132. Van Den Bemt B.J.F., Zwikker H.E., Van Den Ende C.H.M. Medication adherence in patients with rheumatoid arthritis: A critical appraisal of the existing literature // Expert Review of Clinical Immunology. Expert Rev Clin Immunol, 2012. Vol. 8, № 4. P. 337–351.

133. Коллектив авторов. Клинические рекомендации “Падения у пациентов пожилого и старческого возраста”. 2020.

134. Shah B.M., Hajjar E.R. Polypharmacy, Adverse Drug Reactions, and Geriatric Syndromes // Clinics in Geriatric Medicine. Clin Geriatr Med, 2012. Vol. 28, № 2. P. 173–186.

135. Ткачева О.Н. et al. Недостаточность питания (мальнутриция) у пациентов пожилого и старческого возраста. Клинические рекомендации // Russ. J. Geriatr. Med. Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology, 2021. Vol. 0, № 1. P. 15–34.

136. Lavan A.H., Gallagher P.F., O’Mahony D. Methods to reduce prescribing errors in elderly patients with multimorbidity // Clinical Interventions in Aging. Dove Medical Press Ltd., 2016. Vol. 11. P. 857–866.

137. Kojima G. et al. Frailty predicts trajectories of quality of life over time among British community-dwelling older people // Qual. Life Res. Springer International Publishing, 2016. Vol. 25, № 7. P. 1743–1750.

138. Lee I.C., Chiu Y.H., Lee C.Y. Exploration of the importance of geriatric frailty on health-related quality of life // Psychogeriatrics. Blackwell Publishing Ltd, 2016. Vol. 16, № 6. P. 368–375.

139. Fu W.W. et al. Predictors of falls and mortality among elderly adults with traumatic brain injury: A nationwide, populationbased study // PLoS One. Public Library of Science, 2017. Vol. 12, № 4.

140. Yun H. et al. The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population // Br. J. Clin. Pharmacol. Blackwell Publishing Ltd, 2015. Vol. 80, № 6. P. 1447–1457.

141. Martin W.J. et al. Older age at rheumatoid arthritis onset and comorbidities correlate with less health assessment questionnaire-disability index and clinical disease activity index response to etanercept in the RADIUS 2 registry // J. Clin. Rheumatol. Lippincott Williams and Wilkins, 2014. Vol. 20, № 6. P. 301–305.

142. Bressolle F. et al. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients // Ann. Rheum. Dis. BMJ Publishing Group, 1998. Vol. 57, № 2. P. 110–113.

143. Hider S.L. et al. Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? // Ann. Rheum. Dis. BMJ Publishing Group Ltd, 2009. Vol. 68, № 1. P. 57–62.

144. Strangfeld A. et al. Treatment benefit or survival of the fittest: What drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? // Ann. Rheum. Dis. Ann Rheum Dis, 2011. Vol. 70, № 11. P. 1914–1920.

145. Iwanaga N. et al. Risk factors of adverse events during treatment in elderly patients with rheumatoid arthritis: an observational study // Int. J. Rheum. Dis. Blackwell Publishing, 2017. Vol. 20, № 3. P. 346–352.

146. Listing J. et al. Mortality in rheumatoid arthritis: The impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab // Ann. Rheum. Dis. BMJ Publishing Group, 2015. Vol. 74, № 2. P. 415–421.

147. Tikkanen P. et al. Effects of comprehensive geriatric assessment-based individually targeted interventions on mobility of pre-frail and frail community-dwelling older people // Geriatr. Gerontol. Int. Blackwell Publishing, 2015. Vol. 15, № 1. P. 80–88.

148. Matcham F. et al. The prevalence of depression in rheumatoid arthritis: A systematic review and meta-analysis // Rheumatol. (United Kingdom). Rheumatology (Oxford), 2013. Vol. 52, № 12. P. 2136–2148.

149. Drosselmeyer J. et al. Depression risk in patients with lateonset rheumatoid arthritis in Germany // Springer.

150. Ang D.C. et al. Comorbid Depression Is an Independent Risk Factor for Mortality in Patients with Rheumatoid Arthritis. 2005.

151. Ogdie A. et al. Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis // Rheumatol. (United Kingdom). Oxford University Press, 2017. Vol. 56, № 6. P. 907–911.

152. Miwa Y. et al. Clinical characteristics of rheumatoid arthritis patients achieving functional remission with six months of biological DMARDs treatment // Intern. Med. Japanese Society of Internal Medicine, 2017. Vol. 56, № 8. P. 903–906.

153. Michelsen B. et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study // Ann. Rheum. Dis. BMJ Publishing Group, 2017. Vol. 76, № 11. P. 1906–1910.

154. Richards B.L., Whittle S.L., Buchbinder R. Antidepressants for pain management in rheumatoid arthritis // Cochrane Database Syst. Rev. Wiley, 2011. № 11.

155. Holvast F. et al. Non-pharmacological treatment for depressed older patients in primary care: A systematic review and meta-analysis // PLoS ONE. Public Library of Science, 2017. Vol. 12, № 9.

156. Rajbhandary R., Khezri A., Panush R.S. Rheumatoid cachexia: What is it and why is it important? // Journal of Rheumatology. J Rheumatol, 2011. Vol. 38, № 3. P. 406–408.

157. El Maghraoui A. et al. Does rheumatoid cachexia predispose patients with rheumatoid arthritis to osteoporosis and vertebral fractures? // J. Rheumatol. Journal of Rheumatology, 2015. Vol. 42, № 9. P. 1556–1562.

158. Cruz-Jentoft A.J. et al. Sarcopenia: European consensus on definition and diagnosis // Age Ageing. Age Ageing, 2010. Vol. 39, № 4. P. 412–423.

159. He H. et al. Relationship of sarcopenia and body composition with osteoporosis // Osteoporos. Int. Springer-Verlag London Ltd, 2016. Vol. 27, № 2. P. 473–482.

160. Verschueren S. et al. Sarcopenia and its relationship with bone mineral density in middle-aged and elderly European men // Osteoporos. Int. Osteoporos Int, 2013. Vol. 24, № 1. P. 87–98.

161. Adachi J.D. et al. Impact of prevalent fractures on quality of life: Baseline results from the global longitudinal study of osteoporosis in women // Mayo Clin. Proc. Elsevier Ltd, 2010. Vol. 85, № 9. P. 806–813.

162. Landi F. et al. Sarcopenia and mortality risk in frail olderpersons aged 80 years and older: Results from iLSIRENTE study // Age Ageing. Age Ageing, 2013. Vol. 42, № 2. P. 203–209.

163. Smith T. et al. Pre-operative indicators for mortality following hip fracture surgery: A systematic review and metaanalysis // Age Ageing. Oxford University Press, 2014. Vol. 43, № 4. P. 464–471.

164. Lusa A.L. et al. Indicators of walking speed in rheumatoid arthritis: Relative influence of articular, psychosocial, and body composition characteristics // Arthritis Care Res. John Wiley and Sons Inc., 2015. Vol. 67, № 1. P. 21–31. Co-Morbidity in Rheumatoid Arthritis // Frontiers in Nutrition. Frontiers Media S.A., 2014. Vol. 1.

165. Abizanda P. et al. Effects of an oral nutritional supplementation plus physical exercise intervention on the physical function, nutritional status, and quality of life in frail institutionalized older adults: The ACTIVNES study // J. Am. Med. Dir. Assoc. Elsevier Inc., 2015. Vol. 16, № 5. P. 439.e9–439.e16.

166. Karapolat H. et al. Comparison of group-based exercise versus home-based exercise in patients with ankylosing spondylitis: Effects on Bath Ankylosing Spondylitis Indices, quality of life and depression // Clin. Rheumatol. Clin Rheumatol, 2008. Vol. 27, № 6. P. 695–700.

167. Metsios G.S., Stavropoulos-Kalinoglou A., Kitas G.D. The role of exercise in the management of rheumatoid arthritis // Expert Review of Clinical Immunology. Taylor and Francis Ltd, 2015. Vol. 11, № 10. P. 1121–1130.

168. Semerano L. et al. Nutrition and chronic inflammatory rheumatic disease // Joint Bone Spine. Elsevier Masson SAS, 2017. Vol. 84, № 5. P. 547–552.

169. Gioxari A. et al. Intake of ω-3 polyunsaturated fatty acids in patients with rheumatoid arthritis: A systematic review and metaanalysis // Nutrition. Elsevier Inc., 2018. Vol. 45. P. 114–124.e4.

170. Shiboski C.H. et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren’s Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts // Arthritis Rheumatol. John Wiley and Sons Inc., 2017. Vol. 69, № 1. P. 35–45.


Для цитирования:


Мешков А.Д., Остапенко В.С. Особенности лечения воспалительных ревматических заболеваний у пожилых. Российский журнал гериатрической медицины. 2021;(3):327-339. https://doi.org/10.37586/2686-8636-3-2021-319-331

For citation:


Meshkov A.D., Ostapenko V.S. Features of inflammatory rheumatic diseases treatment in older people. Russian Journal of Geriatric Medicine. 2021;(3):327-339. (In Russ.) https://doi.org/10.37586/2686-8636-3-2021-319-331

Просмотров: 61


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2686-8636 (Print)
ISSN 2686-8709 (Online)